TGFB1 and systemic sclerosis: The blockade of type I collagen-related signaling, mainly TGF-β, has received attention as an anti-fibrosis treatment in SSc [13,14], but there has been little research focused on the direct inhibition of α1(I) and α2(I) collagen.